Cell and Gene Therapy
Cell and gene therapies offer potential cures for some of the most devastating and challenging conditions of our time. With our cell and gene product development expertise, TTP is enabling leading companies to commercialise and realise the full potential of their innovative cell therapies.
Commercialising Cell Therapies
We support companies to create bespoke manufacturing tools and equipment, reducing cost of goods and addressing variability and safety challenges, while scaling up new innovations.
We combine our extensive experience of bioprocessing and cell handling, with our understanding of developing highly reliable medical devices – an approach we call Cell Therapy as a Medical Device (CTMD).
Why TTP – Cell and Gene Product Development
Inventive
We develop bespoke solutions and disruptive new technologies for cell and gene therapies. Our cell and gene product development helps clients to commercialise their products, reduce costs and complexities, while also improving access and scalability of their ideas.
Experienced
To date, we have completed over 20 projects for leading companies, enabling cell therapy automation and improving cell therapy manufacturing. Our 30-year bioprocess heritage allows us to anticipate and solve potential challenges across the entire cell and gene product development process.
Partners
We work as an extension of your team, supporting you to challenge conventional thinking. Together, we can create and accelerate existing ideas into successful and commercially viable cell and gene therapies.
Cell and Gene Product Development Expertise
Strategy and planning
Navigating change, identifying business opportunities, balancing risk, timeline and cost from opportunity to launch.
Technology development
First-principles research, inventing enabling solutions and protecting Intellectual Property.
Software integration
GAMP 5 compliant software that connects your solution to MES/EBR systems.
Analytics, measurement and QC solutions
Combining expertise in sensing, molecular and cell biology, microfluidics, electronics, optics and AI.
Automation and instrumentation development
Flexible, highly-skilled and bespoke multi-disciplinary teams developing your solution, including biology to hardware integration, biology development and optimisation.
Prototyping and early stage manufacture
Manufacture of up to 100s of instruments and 1000s of cartridges.
Regulated development
Design of 13485 or GAMP 5 compliant systems, suitable for GMP manufacture.
Usability
Human factors assessment, design for usability, use error analysis.
Late stage troubleshooting
Rapid and scientific approach enables an informed, risk-based response.
Developing a cell-centric approach to electroporation
We are seeking partners to deploy our electroporator commercially
Cell and gene therapy companies need safe, efficient and scalable transfection methods to reduce development costs and ease transition to commercial manufacture.
Electroporation is seen as an attractive alternative to viral vectors, but users often face a trade-off between transfection efficiency and maintaining cell viability. In addition, electroporation platforms used in process development may be unsuitable for scale-up to manufacturing.
Recognising these challenges, we have developed a solution that draws on TTP’s track record in developing cell processing consumables integrating a custom electronic design.
Our solution addresses the challenges of non-viral transfection methods.
- Unrivalled uniformity in cell processing conditions
- Enhanced cell viability at peak efficiency
- Readily scalable from R&D to manufacturing
To learn more about how our solution has been designed to be “gentle” on cells and how it compares to existing bulk electroporation solutions, please download our technology brochure.
Download our ‘Developing a cell-centric approach to electroporation’ Brochure
Case studies
News & Insights
Non-contact cell counting enables in-line, real-time monitoring of manufacturing processes
TTP introduces Cellular Origins, a TTP Company focussed on delivering scalable manufacture of cell and gene therapies
Cell Therapy Scaling: Beyond the Biology
GEN: Cellular Highways at TTP
TTP plc spin-out Cellular Highways Ltd to commercialise next-generation cell sorting technology
How is cell and gene therapy innovation adapting to a changing investment landscape? Insights from TTP’s Cell & Gene panel event
What failure rate are we willing to accept in cell therapy manufacture? Insights from medical device development
Special Delivery: can advanced intracellular delivery enable superior cell therapies for solid tumour treatment – and beyond?
How many cells should a therapeutic cell sorter sort? (Part 1)
How many cells should a therapeutic cell sorter sort? (Part 2)
How many cells should a therapeutic cell sorter sort? (Part 3)
Predicting failure rates in cell therapy manufacturing: is one in a million good enough?
Driving Cell Therapy Innovation: Applying Key Lessons from the Evolution and Commercialization of Protein-Based Therapies
Accelerating medical device development: Lessons from CoVent and the UK ventilator challenge
Who should lead the charge in cell therapy manufacturing?
